Headaches caused by migraines often become unbearable.
But for thousands of sufferers of this health problem, a standard treatment may be the best case scenario that only offers permanent relief.
Related to this, it was found that last year a new injectable drug was being described as life-changing for patients who used it.
Aimovig – also known as erenumab – is the first treatment that aims to disrupt the process that leads to migraine symptoms.
The drug contains cloned immune cells that block a mechanism that causes blood vessels in the brain to swell, leading to an attack.
Clinicians claimed it was 'one of the most significant advances in migraine therapy in decades'.
However, earlier this month, patients were dealt a major blow when the National Institute for Health and Care Excellence (NICE) – the watchdog of NHS spending for England and Wales – refused to fund it, even though health chiefs in Scotland have already given it the green light.
edition
t7 live
